CDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2025-03-14), Conduit Pharmaceuticals's share price is $1.085. Conduit Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-24.52. Therefore, Conduit Pharmaceuticals's PE Ratio without NRI for today is At Loss.
Conduit Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was $-6.62. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-24.52.
As of today (2025-03-14), Conduit Pharmaceuticals's share price is $1.085. Conduit Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.00. Therefore, Conduit Pharmaceuticals's PE Ratio (TTM) for today is At Loss.
Conduit Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was $-7.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.00.
Conduit Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2024 was $-7.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-19.00.
The historical data trend for Conduit Pharmaceuticals's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
PE Ratio without NRI | N/A | N/A | At Loss |
Conduit Pharmaceuticals Quarterly Data | |||||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PE Ratio without NRI | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
At Loss | At Loss | At Loss | At Loss | At Loss |
For the Biotechnology subindustry, Conduit Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Conduit Pharmaceuticals's PE Ratio without NRI for today is calculated as
PE Ratio without NRI | = | Share Price | / | EPS without NRI |
= | 1.085 | / | -24.520 | |
= | -0.04(At Loss) |
Conduit Pharmaceuticals's Share Price of today is $1.085.
Conduit Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Conduit Pharmaceuticals (NAS:CDT) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Regan | director, 10 percent owner | LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133 |
Intelmed Llc | other: See Responses | 11421 GOLDEN EAGLE COURT, NAPLES FL 34120 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
David Tapolczay | director, officer: Chief Executive Officer | 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
Algo Holdings, Inc. | 10 percent owner, other: See Responses | 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309 |
Corvus Capital Ltd. | 10 percent owner, other: See Responses | WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
James Bligh | director | 38 OXBERRY AVENUE, LONDON X0 SW6 5SS |
Shaolin Capital Management Llc | 10 percent owner | 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127 |
Richard Edward Feinberg | director | 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103 |
Murphy Canyon Acquisition Sponsor, Llc | 10 percent owner | 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123 |
Chele Chiavacci Farley | director | 4 RIDGE ROAD, TUXEDO PARK NY 10987 |
Bentzen Edwin H Iv | officer: Chief Accounting Officer | 2513 BIRCH HOLLOW ST, HENDERSON NV 89044 |
Jack Kendrick Heilbron | director, officer: CEO, President, and Chairman | 16433 BRONCO LANE, POWAY CA 92064 |
From GuruFocus
By Marketwired • 07-16-2024
By Marketwired • 11-01-2024
By Marketwired • 11-04-2024
By Marketwired • 11-21-2024
By Marketwired • 11-19-2024
By Marketwired • 02-13-2025
By Marketwired • 08-12-2024
By Marketwired • 01-28-2025
By Marketwired • 06-13-2024
By Marketwired • 09-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.